PerspectiveBIOMEDICAL POLICY

Scientific considerations for global drug development

See allHide authors and affiliations

Science Translational Medicine  29 Jul 2020:
Vol. 12, Issue 554, eaax2550
DOI: 10.1126/scitranslmed.aax2550

Article Information

vol. 12 no. 554

PubMed: 
Print ISSN: 
Online ISSN: 
History: 
  • Received for publication March 7, 2019
  • Resubmitted June 5, 2019
  • Accepted for publication November 5, 2019
  • .

Author Information

  1. Jennifer L. Wilson1,*,
  2. Kit Wun Kathy Cheung1,*,
  3. Lawrence Lin1,
  4. Elizabeth A. E. Green1,
  5. Analia I. Porrás2,
  6. Ling Zou1,
  7. David Mukanga3,
  8. Paul A. Akpa4,
  9. Delese Mimi Darko5,
  10. Rae Yuan6,
  11. Sheng Ding7,8,
  12. Wiltshire C. N. Johnson9,
  13. Howard A. Lee10,11,
  14. Emer Cooke12,
  15. Carl C. Peck1,13,
  16. Steven E. Kern3,
  17. Dan Hartman3,
  18. Yoshikazu Hayashi14,
  19. Peter W. Marks15,
  20. Russ B. Altman16,
  21. Murray M. Lumpkin3,
  22. Kathleen M. Giacomini1, and
  23. Terrence F. Blaschke17
  1. 1Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, CA, USA.
  2. 2Medicines and Health Technologies Unit, Department of Health Systems and Services, Pan American Health Organization, Regional Office of the World Health Organization, Washington, DC, USA.
  3. 3Global Health, Bill and Melinda Gates Foundation, Seattle, WA, USA.
  4. 4Department of Pharmaceutics, University of Nigeria, Nsukka, Enugu State, Nigeria.
  5. 5Food and Drugs Authority, Accra, Ghana.
  6. 6Sinovant Sciences Co., Shanghai, China.
  7. 7School of Pharmaceutical Sciences, Tsinghua University, Beijing, China.
  8. 8Gladstone Institute of Cardiovascular Disease, San Francisco, CA, USA.
  9. 9Pharmacy Board of Sierra Leone, Freetown, Sierra Leone.
  10. 10Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea.
  11. 11Department of Transdisciplinary Studies, Graduate School of Convergence Science and Technology, Seoul National University, Suwon, Republic of Korea.
  12. 12World Health Organization, Geneva, Switzerland.
  13. 13NDA Partners LLC, San Luis Obispo, CA, USA.
  14. 14Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.
  15. 15Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA.
  16. 16Departments of Bioengineering and Genetics, Stanford University, Stanford, CA, USA.
  17. 17Departments of Medicine and Molecular Pharmacology, Stanford University School of Medicine, Stanford, CA, USA.
  1. Corresponding author. Email: kathy.giacomini{at}ucsf.edu
  • * These authors contributed equally to this work.

Altmetric

Article usage

Article usage: July 2020 to October 2020

AbstractFullPdf
Jul 20201378307121
Aug 20201115336143
Sep 20201916437
Oct 20201161825

Stay Connected to Science Translational Medicine